stockrow
Friday 6 November 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.5%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
166.96
0.61
−0.36%
Follow GILD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
17.92 | 18.78 | 0.00 | 0.00 |
P/S ratio |
5.19 | 5.82 | 5.16 | 5.97 | |
P/FCF ratio |
16.15 | 16.92 | 12.13 | 13.43 | |
P/Operating CF |
45.89 | 68.04 | 43.95 | 36.77 | |
P/B ratio |
6.75 | 7.39 | 13.37 | 14.29 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.77 | 6.31 | 5.91 | 6.61 | |
EV/EBITDA |
13.30 | 14.30 | 687.43 | 454.36 | |
EV/Operating CF |
16.97 | 17.36 | 13.29 | 14.15 | |
EV/FCF |
17.98 | 18.34 | 13.92 | 14.87 | |
Quick Ratio |
1.06 | 1.31 | 0.75 | 0.95 | |
Current Ratio |
1.55 | 1.97 | 1.27 | 1.32 | |
Net Debt/EBITDA |
6.48 | 4.44 | (2.38) | 4.71 | |
Debt/Assets |
42.25% | 39.40% | 53.17% | 51.03% | |
Debt/Equity |
1.10 | 0.95 | 2.23 | 2.02 | |
Asset Turnover |
0.50 | 0.53 | 0.58 | 0.56 | |
Operating CF/Net income |
1.52 | 1.26 | (0.34) | 2.07 | |
Capex/Depreciation |
(0.30) | (0.17) | (0.20) | (0.32) | |
Interest Coverage |
7.81 | 10.77 | (42.08) | 12.87 | |
Research and Development Expense of Revenue |
19.97% | 19.71% | 22.61% | 19.37% | |
Selling, General and Administrative Expense of Revenue |
22.64% | 20.85% | 24.62% | 19.77% | |
Intangible Assets out of Total Assets |
0.43 | 0.44 | 0.45 | 0.42 | |
Share Based Compensation of Revenue |
2.90% | 3.13% | 2.96% | 2.82% | |
Graham Net Nets |
(0.12) | (0.08) | (0.15) | (0.12) | |
Graham Number |
52.94 | 56.12 | 0.00 | 0.00 | |
Earnings Yield |
5.58% | 5.32% | (2.06%) | (2.08%) | |
Free Cash Flow Yield |
6.19% | 5.91% | 8.24% | 7.44% | |
Revenue per Share |
6.37 | 5.60 | 6.28 | 6.68 | |
Operating CF per Share |
2.67 | 2.05 | 2.87 | 4.05 | |
Capex per Share |
(0.16) | (0.09) | (0.11) | (0.19) | |
Free Cash Flow per Share |
2.51 | 1.95 | 2.76 | 3.86 | |
Cash per Share |
6.14 | 6.15 | 2.56 | 5.18 | |
Shareholders Equity per Share |
18.18 | 18.87 | 9.45 | 10.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.18 | 18.87 | 9.45 | 10.43 | |
Free Cash Flow |
3,122.00 | 2,427.00 | 3,433.00 | 4,798.00 | |
Working Capital |
6,529.00 | 9,165.00 | 2,925.00 | 3,866.00 | |
Capital Expenditures |
(205.00) | (117.00) | (140.00) | (237.00) | |
Net Current Asset Value |
(18,063.00) | (14,206.00) | (23,673.00) | (22,585.00) | |
EV/EBIT |
16.96 | 18.09 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
15.24 | 16.69 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4,666.50 | 4,564.50 | 4,918.00 | 5,051.00 | |
Average Payables |
774.00 | 691.00 | 628.00 | 871.00 | |
Average Inventory |
1,742.00 | 1,836.50 | 1,889.00 | 3,104.50 | |
Average Assets |
59,009.00 | 56,356.00 | 52,541.50 | 54,970.50 | |
Average Common Equity |
20,932.00 | 21,254.50 | 15,667.50 | 17,205.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026